Resposne Pharmaceuticals Initates RDX-002 Phase 2 Study Weight management
Response Pharmaceuticals, a clinical-stage company specializing in weight management and metabolic health, has begun enrolling participants in a Phase...
Terray Therapeutics Raises $120M in Series B Funding
Terray Therapeutics, a biotechnology company revolutionizing small molecule drug development, has secured $120 million in Series B funding. This...
Verastem Presents Positive Updated Data for Atutometinib
Verastem Oncology, a company dedicated to developing cancer treatments, has released promising data from its Phase 2 RAMP 201...
Expert Strategies for FDA LDT Compliance: Meeting the 1st Milestone
Clinical laboratories face a critical deadline: achieving Phase One compliance with the FDA’s Laboratory Developed Test (LDT) rule by...
Charles River Launches New Retrogenix® Protein Library
Charles River Laboratories International, Inc. has introduced the Retrogenix® Non-Human Protein Library, a tool designed to assist biopharmaceutical companies...
AN2 Receives Grant for Boron-Based Therapies for Tuberculosis
AN2 Therapeutics, a biopharmaceutical company specializing in boron chemistry-based therapeutics, has secured continued research funding from the Bill &...
Cefiderocol Shows Strong Clinical Response in Global Study
Shionogi & Co., Ltd. has released new data from PROVE, a large-scale global study examining real-world evidence for Fetroja®/Fetcroja®...
Gilead Reveals Remarkable Findings in HIV Prevention Trial: Encouraging News for a Devastating Disease
Gilead Sciences has reported promising data from its Phase 3 PURPOSE 2 trial, demonstrating the efficacy and safety of...
Airsupra Reduces Severe Asthma Attacks: A Game-Changer for Patients
A clinical trial (BATURA) has shown the efficacy of AstraZenaca’s AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma...
New HPV Vaccine Trial Gives Hope to Cancer Patients
TheraVectys, a biotechnology company specializing in lentiviral vector-based vaccines and immunotherapies, has begun enrolling patients in a Phase I/IIa...